Research

Clinical trial results confirm that stem cells are safe and effective in the treatment of psoriasis

    Recently, Xiangya Hospital of Central South University published the latest research results of the clinical research project "Human umbilical cord-derived mesenchymal stem cells in the treatment of psoriasis". The results showed that allogeneic umbilical cord mesenchymal stem cell transplantation was safe and partially effective in patients with psoriasis, with an effective rate of 25% in men and 66.7% in women. This study evaluated the safety and efficacy of human umbilical cord-derived mesenchymal stem cells in the treatment of psoriasis, and analyzed the possible mechanism of action, representing a major breakthrough in the field of stem cell therapy for psoriasis clinical research in my country.

    The research is divided into two phases:

       Phase 1, from March to September 2019, patients were screened, and patients received stem cell injection every 2 weeks, a single dose of 1.5 × 10^6/kg, 4 times as a course of treatment, 15 days after treatment , 30 days, 45 days, 2 months, 3 months and 6 months were followed up respectively.

       In the second phase, from September 2019 to August 2020, the researchers set up 4 dose-escalating stem cell groups (1.5, 2.0, 2.5, 3.0 × 10^6/kg). Patients were screened and randomly divided into 4 groups. The first and second patients received an intravenous infusion of stem cells every 15 days, 4 times as a course of treatment. The third and fourth groups of patients received stem cells intravenously every 30 days, 2 times as a course of treatment.

    The results of the study showed that no significant side effects were found in each dose group, and even patients in the high-dose group (the number of cells infused 2.4 × 10^8) showed no obvious side effects after infusion, including fever and thrombosis.

The skin symptoms of some patients before and after treatment in this study were compared: